Navigation Links
Why prostate cancer patients fail hormone deprivation therapy
Date:12/31/2008

The hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, with tumors usually regaining their hold within a couple of years. Now, researchers at Johns Hopkins have discovered critical differences in the hormone receptors on prostate cancer cells in patients who no longer respond to this therapy. The findings, reported in the Jan. 1 issue of Cancer Research, could lead to a way to track disease progression, as well as new targets to fight prostate cancer.

Prostate cancer cells rely on androgens, male hormones that include testosterone, to survive and grow, explains Jun Luo, Ph.D., an assistant professor at Johns Hopkins' James Buchanan Brady Urological Institute. Since 1941, doctors have taken advantage of this dependency to battle prostate cancer by depriving patients of androgens, either by castration or chemical methods. For most patients, this hormone deprivation therapy causes tumors to shrink, sometimes dramatically. However, it's never a curetumors eventually regrow into a stronger form, becoming resistant to this and other forms of treatment.

Seeking the reason why this therapy eventually fails, Luo and his colleagues at the Johns Hopkins University School of Medicine, the University of Washington and Puget Sound VA Medical Center looked to a key player: the androgen receptors on prostate cancer cells.

Using a large database, the researchers searched for variations of the nucleic acid RNA that prostate cells use to create androgen receptors, eventually identifying seven RNA sequences different from the "normal" androgen receptor already known to scientists. When they looked for these sequences in cells isolated from 124 prostate cancer patients, they found over-production of these outlaw variants in prostate cancer cells taken from patients whose disease had become resistant to hormone deprivation therapy. One variationknown as AR-V7, was also prevalent in a select group of
'/>"/>

Contact: Christen Brownlee
cbrownlee@jhmi.edu
410-955-7832
Johns Hopkins Medical Institutions
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. First biomarker discovered that predicts prostate cancer outcome
3. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
4. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
5. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
6. Red wine compound shown to prevent prostate cancer
7. Barbershop Talks Cut Black Mens Prostate Cancer Risk
8. Generic prostate drug helps find high-risk cancers early
9. Finasteride unlikely to induce high grade prostate cancers
10. Shrinkage of prostate led to overestimation of cancer risk in trial
11. Prostate Cancer Awareness Week to Screen Thousands

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/7/2009)...HOUSTON, Nov. 7 The Ame...Lisa James, Director of Health at the Family Viole...uished Service today at its semi-annual policy-mak...ce is the highest honor the AMA House of Delegates...p://www.newscom.com/cgi-bin/prnh/20081209/AMALOGO ...
(Date:11/7/2009)...HOUSTON, Nov. 7 Calling this a "de...n (AMA), the AMA President J. James Rohack, M.D., ...ians from all state and medical specialty societie...aking meeting, where health system reform will top.../cgi-bin/prnh/20081209/AMALOGO ) ,, "Over the...
(Date:11/7/2009)...WASHINGTON, Nov. 7 With..., antichoice extremists are holding the entire bil...ey are demanding that the bill go far beyond the s...ncorporated into the original bill. In an outrage...rly Saturday afternoon, antichoice Democrats are d...
(Date:11/7/2009)...WASHINGTON, Nov. 7 The ... of Representatives to vote for the Stupak-Ellswor... Stupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski...l law on abortion funding and conscience protectio...H.R. 3962)," they said. ,, The letter was signe...
(Date:11/7/2009)...GTON, Nov. 7 Americans United for Life Action end...tupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-S...al money from going to abortion in health care ref...nt and CEO Dr. Charmaine Yoest said, "Americans Un...Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith A...
Breaking Medicine News(10 mins):Health News:AMA Honors Family Violence Prevention Expert 2Health News:AMA President Kicks Off AMA Meeting Focused on Health Reform 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2Health News:Americans United for Life Action Endorses a Vote for the Stupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Amendment and Sends Score Letter to House Members 2
...The Procter & Gamble,Company (NYSE: PG ) ann...61,percent increase for the October - December qua...m the Folgers transaction completed during the,qua...es were three percent below the year-ago quarter a...
...wo-thirds of Americans classified by the governmen...rent economic environment making it even more diff...ed Dr. Olga Stevko, Clinical Hypnotherapist and MD...individual and group sessions. Dr. Olga and her pr...
...nt and Future Growth Opportunities in Transplant D...an Expansion Strategy - , , SAN DIEGO, Calif., Ja... pioneer and leader in nucleic acid diagnostics fo... rapidly growing molecular diagnostics company bas...
...or, rapid transport, and,artificial blood products...,soldiers during the wars in Iraq and Afghanistan....cal transit from battlefield to combat hospitals i...),could be a viable new option for physicians trea...
...ominate State Fiscal Landscape, AHCA/Alliance Urge...deral Medicaid Funds , , WASHINGTON, Jan. 29 W... for vulnerable populations increasing at an alarm...er that will better protect U.S. seniors, ongoing ...
... Varian Medical,Systems (NYSE: VAR ) today repor...56 per diluted share in the first quarter of fisca...erations of $0.46 per diluted share in the year-ag...,continuing operations in the year-ago quarter, fi...
Other Medicine News:Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 2Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 3Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 4Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 5Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 6Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 7Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 8Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 9Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 10Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 11Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 12Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 13Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 14Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 15Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 16Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 17Health News:Expert Hypnotherapist Dr. Olga Stevko Offers Clients Simple and Powerful Tools for Lasting Weight Loss; Dr. Olga Combines Hypnotherapy and NLP to Transform Clients' Limi 2Health News:Expert Hypnotherapist Dr. Olga Stevko Offers Clients Simple and Powerful Tools for Lasting Weight Loss; Dr. Olga Combines Hypnotherapy and NLP to Transform Clients' Limi 3Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 2Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 3Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 4Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 5Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 6Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 7Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 8Health News:Regional Anesthesia Eases Wounded Soldiers' Pain in Iraq and Afghanistan 2Health News:Regional Anesthesia Eases Wounded Soldiers' Pain in Iraq and Afghanistan 3Health News:Stimulus Bill Requires Modification in U.S. Senate to Better Protect Seniors' Ongoing Access to Quality Nursing Home Care 2Health News:Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2009 2Health News:Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2009 3Health News:Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2009 4Health News:Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2009 5Health News:Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2009 6Health News:Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2009 7
(Date:11/5/2009)...lthea Technologies, Inc., a leading provider of de...ceutical products announced the addition of custom...form of services, which will be overseen by the ne...ulation Development. This investment in an experie..., along with new laboratory facilities and state-o...
(Date:11/5/2009)...FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HB...II trial of Topical Interferon Alpha-2b for the tr...atient enrollment, with the required 120th patient...lind and placebo-controlled Phase II trial is unde...atients participating in the trial self-administer...
(Date:11/5/2009)...e/ -- Renee Cobos, MD, a board certified dermatolo... University of California, Irvine, announced today...ults with Thermage CPT®. The updated system, ...ng, features a new vibrating hand piece that incre...rt. ,, "Thermage has always been popular with ...
Breaking Medicine Technology:Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 2Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 3Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 4Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 5Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 6Orange County Dermatologist Garners Outstanding Results With New Thermage CPT(R) 2Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk 4797 1Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk 4797 2Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk 4797 3Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk 4797 4The San Francisco SPCA Launches Online Guide for Summer Pet Health 26 Safety 53233 1The San Francisco SPCA Launches Online Guide for Summer Pet Health 26 Safety 53233 2The San Francisco SPCA Launches Online Guide for Summer Pet Health 26 Safety 53233 3Governor Eliminates Funding to Domestic Violence Programs 53230 1Governor Eliminates Funding to Domestic Violence Programs 53230 2
...rimary Endpoint for Clinical,Trials; Data Presente...ongress -, SOUTH PLAINFIELD, N.J., Sept. 30 PTC ... findings in patients with Duchenne/Becker,Muscula...rld Muscle Society,(WMS) Congress. Results from an...6-minute walk test (6MWT) as a primary outcome mea...
... AMD patients, LOUISVILLE, Ky., Sept. 29 Potenti...company developing medicines for the treatment,of ...oday that the,Company,s leading drug candidate, PO...s Phase I study. POT-4 is a complement inhibitor, ... that could otherwise lead to local,inflammation, ...
Other Medicine Technology:PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy 4PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy 5Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4 2
Cypher Stent
PT2LS Guide Wire (light support)
Fort Floppy
Lieberman Wire Angled Speculum
Medicine Products: